Status:
COMPLETED
A Study of Monthly Subcutaneous or Intravenous Mircera in Dialysis Patients With Chronic Renal Anaemia
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Anemia
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This open label, single arm study will assess the efficacy for long-term maintenance of haemoglobin levels and the safety and tolerability of methoxy polyethylene glycol-epoetin beta \[Mircera\] in di...
Eligibility Criteria
Inclusion
- adult patients, \>/=18 years of age
- chronic renal anaemia
- haemoglobin 10.0-12.0g/dl at screening
- adequate iron status
- continuous stable ESA (erythropoietic stimulating agent) therapy for \>/= 2 months
- regular haemodialysis or regular peritoneal dialysis for \>/= 3 months
Exclusion
- uncontrolled hypertension
- haemoglobinopathy
- anaemia due to haemolysis
- pure red cell aplasia (PRCA)
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2013
Estimated Enrollment :
86 Patients enrolled
Trial Details
Trial ID
NCT01156363
Start Date
October 1 2010
End Date
January 1 2013
Last Update
December 3 2015
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaohsiung City, Taiwan, 807
2
New Taiepei City, Taiwan
3
Taichung, Taiwan, 404